Showing 4611-4620 of 6411 results for "".
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu
- Weekly Cendakimab Dosing Effective in Reducing AD Severityhttps://practicaldermatology.com/news/weekly-cendakimab-dosing-effective-reducing-ad-severity/2467489/New research shows that cendakimab is safe and efficacious at certain dosing levels over a 16-week study period in patients with moderate-to-severe atopic dermatitis (AD). The study authors for the phase 2 trial included 221 adult patients with moderate-to-severe AD from the United States
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Analysis: Ruxolitinib 1.5% Cream Linked with Repigmentation in Adolescents with Vitiligohttps://practicaldermatology.com/news/phase-3-trials-reveal-enhanced-repigmentation-adolescents-vitiligo/2467443/A new post-hoc analysis indicates significant repigmentation results from the application of 1.5% ruxolitinib cream in patients with nonsegmental vitiligo. The analysis looked at two double-blind, vehicle-controlled studies (the TRuE-V1 and TRuE-V2 phase 3 clinical trials). Patients were
- Powered By MRP Gets Series A Investmenthttps://practicaldermatology.com/news/powered-mrp-gets-series-investment/2467442/“Strong tailwinds behind the aesthetics market” was part of the impetus for two prominent growth equity firms to form a strategic partnership with aesthetics device company Powered By MRP, according to a press release. The Series A investment by Aries Capital Partners and Swell Collective
- Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial of Androgenetic Alopecia Treatmenthttps://practicaldermatology.com/news/dermaliq-therapeutics-announces-positive-topline-results-phase-1b2a-trial-androgenetic-alopecia-treatment/2467422/Dermaliq Therapeutics announced statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older